Formulary Watch reports that the FDA has expanded the indication for the Pfizer drug palbociclib to treat breast cancer in male patients. Janet Serluco, VP, Access Experience Team, Oncology Lead at Precision Medicine Group, comments on the implications for patients and for Pfizer.
As legislative efforts have changed the 340 Drug Discount Program, payers, specialty pharmacies and health systems have been impacted. Precision for Value experts Dominic Galante, Chief Medical Officer, and Linda R. Bolland, senior advisor, discuss the factors affecting the program today in an exclusive video on Specialty Pharmacy Continuum.
More than 90 million people are covered by payers with a copay accumulator program—but patient advocates are fighting back. Jeremey Shafer, Senior VP, Access Experience Team, Precision for Value, believes the advocates will be successful. Discover why in Radar on Specialty Pharmacy. (more…)
Gene therapies offer tremendous promise—yet their high upfront cost has been a challenge for payers. Kellie Rademacher, Precision for Value’s VP, Access Experience Team, outlined the pros and cons in a talk at the Association of Managed Care Pharmacy Annual Meeting; Managed Healthcare Executive reports on it.
Authorized generics allow drug manufacturers to tout a cost-conscious option—and ultimately to compete with other generics. But what does that mean for payers and consumers? Precision’s Jeremey Shafer, senior VP and director of the Access Experience Team, shares insights on the pricing intricacies in this Spotlight on Market Access article.
What does the future hold for the manufacturing and clinical landscape? Pharma iQ asked Precision leaders Scott Marshall, PhD and Jeremy Schafer, PharmD, MBA. From gene therapy cures for chronic diseases to continuing price pressure on manufacturers, the role of machine learning to the role of companion diagnostics, their insights point the way to major developments in 2019.
To read the full article, click here
Careful planning, improving access to care, and managing pain, depression and side effects are logical paths to better oncology care. Three Precision for Value experts—Larry Blandford, Executive Vice President, Managing Partner; Maureen Hennessey, Senior Vice President, Director of Value Transformation; and Linda Bolland, Senior Advisor, explain how in the Journal of Clinical Pathways.
To read the full article, click here
Gene therapies offer the promise of a one-and-done treatment for debilitating chronic disease—but payers still have lots of questions—from patient selection to duration of response. In this Clinical Leader article, Jeremy Schafer, PharmD, MBA, Senior Vice President of specialty solutions at Precision for Value, describes how well-designed clinical trials can answer these questions.
To read the full article, click here
Today’s miraculous new therapies come with dramatic new price tags. Radar on Specialty Pharmacy asks what that means for payers and patients. Jeremy Schafer, Precision for Value Senior Vice President of Specialty Solutions, shares industry thinking and his own insights.
To read the full article, please see below
What top game-changing therapies will rock 2019 and deliver long-lasting consequences? Managed Healthcare Executive asked 7 industry leaders; Andrew Cournoyer, Precision for Value Vice President, Director, Payer Access Solutions, shares his vote.
To read the full article, click here